Huons is working on 'Probiotics and Microbiome' to secure next-generation growth engines in future bio areas.
Huons announced on January 28 that it signed a joint research and development agreement on diagnosis and treatment solutions using Microbiome platform technology with Genome & Company, which specializes in microbaiom, at its headquarters in Pangyo, Seongnam on January 25.
The main content is to develop diagnostic treatment solutions by combining Huons' various products such as professional medicine, health food products, and medical devices with the Microbiome database of Ginom & Company.
Huons and Ginom & Company establish a predictive model by correlating the patient's Microbiome data with the data obtained from clinical trials.
In the future, Microbiome's analysis is expected to help predict the clinical state of patients, which will enable the establishment of new treatment systems and paradigms.
"We are going to actively push forward with developing innovative treatments and solutions in the future." said Eum Ki-an, CEO of Huons.
